Related Experiment Video

Updated: Aug 3, 2025

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells
08:35

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells

Published on: June 12, 2017

10.2K

SGLT2 inhibitors and autophagy in diabetes

Habib Yaribeygi1, Mina Maleki2, Stephen L Atkin3

  • 1Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.

Cell Biochemistry and Function
|April 10, 2023
PubMed

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) may impact cellular autophagy, a process implicated in diabetes complications. This review explores SGLT2is

Area of Science:

  • Cellular Biology
  • Endocrinology
  • Pharmacology

Background:

  • Autophagy is crucial for cell survival but can become pathological in diabetes.
  • Chronic hyperglycemia in diabetes leads to aberrant autophagy and cell death, contributing to complications.
  • Autophagy modulation is a potential therapeutic strategy for diabetic complications.

Purpose of the Study:

  • To review the current evidence on the effects of Sodium-glucose cotransporter 2 inhibitors (SGLT2is) on cellular autophagy.
  • To clarify the potential role of SGLT2is in modulating autophagy in the context of diabetes.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of research investigating the mechanistic links between SGLT2is and autophagy pathways.

Main Results:

  • Evidence suggests SGLT2is may influence autophagy, though direct effects require further investigation.
  • Potential mechanisms include modulation of cellular energy status and oxidative stress.
  • Understanding these effects could explain some of the extra-glycemic benefits of SGLT2is.

Conclusions:

  • SGLT2is might exert therapeutic effects in diabetes partly through modulating autophagy.
  • Further research is needed to confirm the direct impact of SGLT2is on autophagy and its clinical relevance.
  • Investigating SGLT2is' effects on autophagy may reveal novel therapeutic targets for diabetic complications.
Keywords:
SGLT2iautophagydiabetes mellitussodium-glucose cotransporter 2 inhibitorssodium-hydrogen exchangers

More Related Videos

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

933
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.1K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
220
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
247
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
373
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
224
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
195
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.8K